Clinical Trial Update: Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of CP-751,871 in combination with exemestane in postmenopausal women with hormone receptor-positive advanced breast cancer was terminated. Resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)
• Exemestane (Exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2015-07-28